Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock increased by 1.77% to $48.21, outperforming competitors on a favorable trading day where the S&P 500 and Dow Jones Industrial Average also saw gains. This marks the fifth consecutive day of gains for the company's stock.
Bio-Techne Corp. stock underperforms Thursday when compared to competitors despite daily gains
Bio-Techne Corp. (TECH) stock saw a 1.43% increase on Thursday, closing at $47.37. Despite this gain and a positive day for the broader market, with the S&P 500 and Dow Jones also rising, Bio-Techne's stock underperformed relative to its competitors. This marks the fourth consecutive day of gains for the company's shares.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) saw its shares advance 2.71% to $46.70 on Wednesday, outperforming the broader market. This marks the third consecutive day of gains for the stock. The S&P 500 Index and Dow Jones Industrial Average also rose significantly on the favorable trading day.
Repligen Jumps 5.4% Amid Sector-Wide Rally
Repligen Corporation (RGEN) stock surged 5.4% to $109.80 on Tuesday, driven by a broad sector-wide rally that also boosted several of its medical instrument supplier peers. The coordinated gains suggest a rotation of investor interest back into the healthcare sector, with heightened trading volume for Repligen reflecting increased activity. No specific company news was identified as the catalyst, indicating the move is likely attributable to broader macro factors or shifting sentiment within the industry.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock advanced 2.34% to $45.47 on Tuesday, outperforming the broader market which saw the S&P 500 Index fall 0.67% and the Dow Jones Industrial Average fall 0.65%. This marked the stock's second consecutive day of gains despite a grim trading session.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) shares rose 2.80% to $44.43 on Monday, outperforming its competitors despite a mixed trading session for the broader market. This gain ended a three-day losing streak for the stock.
Bio-Techne (TECH) price target decreased by 13.49% to 65.35
This article reports that Bio-Techne (TECH) has had its price target decreased by 13.49%, bringing it down to $65.35. The information provided is minimal and appears to be an automated financial update based on recent analyst actions.
Bio-Techne stock hits 52-week low at 44.09 USD
Bio-Techne Corporation's stock has fallen to a 52-week low of $44.09, reflecting a 24% decline over the past six months and year-to-date. Despite this downturn, InvestingPro analysis suggests the stock is undervalued, appearing on their Most Undervalued list. The company also recently reported Q3 2026 financial results that missed analyst expectations, although RBC Capital initiated coverage with an outperform rating and a $62 price target, citing confidence in a sales rebound and the underappreciated acquisition of Wilson Wolf.
Bio-Techne Corp. stock underperforms Friday when compared to competitors
Bio-Techne Corp. (TECH) stock fell 3.22% on Friday, closing at $43.30, marking its third consecutive day of losses. This dip occurred during a negative trading session for the broader market, with the S&P 500 Index decreasing by 1.24% and the Dow Jones Industrial Average falling by 1.07%.
Bio-Techne stock hits 52-week low at 44.09 USD By Investing.com
Bio-Techne's stock has dropped to a 52-week low of $44.09, reflecting a challenging year with significant declines over the past six months and year-to-date. Despite the downturn and recent earnings miss, InvestingPro analysis suggests the stock is undervalued. RBC Capital initiated coverage with an "outperform" rating and a $62.00 price target, citing confidence in sales growth and the underappreciated acquisition of Wilson Wolf.
RBC Capital assumes Bio-Techne stock coverage with outperform rating By Investing.com
RBC Capital has initiated coverage on Bio-Techne Corp. with an outperform rating and a price target of $62.00, expressing confidence in the stock's sales growth rebound and the undervalued acquisition of Wilson Wolf. The analyst noted Bio-Techne is positioned to benefit from an improved biotech funding environment, despite recent financial results falling short of analysts' expectations for Q3 2026. The company currently trades near its 52-week low, but InvestingPro data suggests it is undervalued.
Dorchester Minerals, L.P. - Common Units Representing Limited (NQ: DMLP)
This article provides a stock quote and recent news for Dorchester Minerals, L.P. (DMLP). As of May 15, 2026, the stock is trading at $27.50, up 0.99%, with a dividend yield of 11.00%. The news section highlights recent distribution announcements, management changes, and the acquisition of mineral interests by the company.
MDxHealth (NASDAQ: MDXH) posts Q1 2026 growth and issues new 2026 guidance
MDxHealth reported Q1 2026 revenue of $27.4 million, a 13% increase year-over-year, alongside an operating loss of $7.3 million and a net loss of $8.9 million. The company announced it would discontinue its Resolve UTI business and close its Plano, Texas lab to focus on prostate cancer diagnostics and the ExoDx acquisition. MDxHealth also issued new 2026 core cancer revenue guidance of $110–115 million, representing 20–26% growth, and is contesting a $10.4 million Medicare recoupment decision related to historical Resolve claims.
Bio-Techne Down Over 5%, on Track for Lowest Close Since March 2020 -- Data Talk
Bio-Techne Corporation's stock (BIGT) is down over 5% and is set to close at its lowest point since March 2020. This significant drop follows a downgrade from neutral to sell by Citi, which also reduced the price target from $70 to $58. This negative analyst action has contributed to the stock's substantial intraday decline.
Why Bio-Techne Is Dropping 5.7%: Citigroup Maintains Buy
Bio-Techne Corporation (TECH) plunged 5.7% after Citigroup, Wells Fargo, and Evercore ISI Group all slashed their price targets for the biotechnology company. Despite the reductions, two of the three firms maintained positive ratings, with the revised average price target of $61 still suggesting significant upside from its current $44.73. Investors are now watching for further analyst actions and upcoming company commentary to assess whether the selloff presents a buying opportunity or signals more downside.
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors
Bio-Techne Corp. (TECH) stock underperformed on Wednesday, falling 5.34% to $44.89, while the S&P 500 Index rose and the Dow Jones Industrial Average fell. The stock closed 37.79% below its 52-week high of $72.16, reached on January 22nd. The trading session was mixed for the broader market.
Earnings call transcript: Bio-Techne Q3 2026 misses EPS and revenue targets
Bio-Techne reported Q3 2026 earnings and revenue below analyst expectations, with an adjusted EPS of $0.53 against a forecast of $0.54, and revenue of $311.4 million missing the $316.12 million projection. The company's stock experienced a significant pre-market decline of 10.18% following the announcement. Operational challenges and timing-related headwinds, particularly from cell therapy customers, were cited as factors impacting the 2% organic revenue decline, though strategic initiatives and improving academic and large pharma markets are expected to drive recovery in fiscal 2027.
Earnings call transcript: Bio-Techne Q3 2026 misses EPS and revenue targets
Bio-Techne (NASDAQ: TECH) reported Q3 2026 financial results that missed analyst expectations for both EPS and revenue, leading to a significant drop in its stock price. Despite a 2% organic revenue decline attributed to timing-related headwinds and operational challenges, the company is implementing strategic initiatives like brand consolidation and AI integration for future growth. Bio-Techne remains optimistic about a stronger fiscal year 2027, driven by improving biotech funding, stabilizing academic markets, and sustained demand from large pharmaceutical customers, projecting mid-single-digit growth.
Bio-Techne Insider Sold Shares Worth $320,386, According to a Recent SEC Filing
An insider at Bio-Techne recently sold shares totaling $320,386, as disclosed in a recent SEC filing. This transaction provides insight into insider activity for the company's stock.
Bio-Techne Insider Sold Shares Worth $320,386, According to a Recent SEC Filing
An insider at Bio-Techne (NASDAQ: TECH) recently sold shares valued at $320,386, as reported in a Securities and Exchange Commission (SEC) filing. The company specializes in manufacturing and marketing products for life science research and diagnostics. This transaction follows other recent news for Bio-Techne, including participation in major healthcare conferences and analyst price target adjustments.
Bio-Techne (TECH) director’s linked account exercises options and sells 6,636 shares
Bio-Techne director Amy E. Herr's significant other's account exercised 6,636 stock options and simultaneously sold 6,636 common shares of Bio-Techne (TECH) on May 8, 2026. The options were exercised at $47.60 per share, and the common stock was sold at a weighted average price of approximately $48.28 per share, resulting in a net sale of 6,636 shares valued at $320,386. After the transaction, Herr directly holds 2,680 shares, and her significant other's account holds 200 indirect shares, alongside various remaining stock options and restricted stock units.
Earnings call transcript: Bio-Techne Q3 2026 misses EPS and revenue targets
Bio-Techne reported Q3 2026 earnings and revenue below analyst expectations, with an adjusted EPS of $0.53 against a forecasted $0.54, and revenue of $311.4 million against $316.12 million. This underperformance led to a 10.18% drop in pre-market trading. The company cited operational challenges, timing-related headwinds, and softness in emerging biotech spending, but remains optimistic about future growth driven by strategic initiatives in spatial biology, proteomic analysis, and AI integration.
Earnings call transcript: Bio-Techne Q3 2026 misses EPS and revenue targets
Bio-Techne Corporation reported Q3 2026 financial results, missing EPS and revenue targets with adjusted EPS of $0.53 against a forecasted $0.54, and revenue of $311.4 million compared to a projected $316.12 million. The company's stock dropped over 10% in pre-market trading due to organic revenue decline caused by operational challenges and timing-related headwinds. Despite the setbacks, Bio-Techne is implementing strategic initiatives like brand consolidation and AI integration and remains optimistic about long-term growth, projecting potential outperformance in the coming years.
Insulet Corporation (PODD) Stock Analysis: A 62% Potential Upside Beckons Investors
Insulet Corporation (PODD), a leader in diabetes care with its Omnipod insulin delivery systems, is attracting investor interest due to a potential 62.25% upside based on analyst target prices. Despite a recent stock decline, its strong financials, positive analyst sentiment, and focus on growth-oriented reinvestment signal promising long-term prospects. Investors should, however, evaluate market conditions and risks.
Bio-Techne Corp. stock underperforms Monday when compared to competitors
Bio-Techne Corp. (TECH) shares fell by 1.94% to $47.42 on Monday, underperforming the broader market which saw the S&P 500 Index rise by 0.19% and the Dow Jones Industrial Average also increase by 0.19%. This marks the second consecutive day of losses for the company's stock.
Nicholas Company Inc. Acquires 23,785 Shares of Bio-Techne Corp $TECH
Nicholas Company Inc. increased its stake in Bio-Techne Corp by 6.5% during Q4, adding 23,785 shares to own a total of 390,794 shares valued at $22.98 million. Wall Street analysts have a "Moderate Buy" consensus rating for Bio-Techne with an average price target of $66.77, despite the company recently missing EPS and revenue expectations for its latest quarter. Bio-Techne also declared a quarterly dividend of $0.08 per share.
Bio-Techne profit nearly doubles even as sales slip to $311.4M
Bio-Techne reported its Q3 fiscal 2026 results with net sales of $311.4 million, a 2% decline year-over-year, while GAAP EPS significantly increased to $0.32 from $0.14. Despite the sales slip, GAAP operating income rose by 95% to $75.5 million, and operating margin improved to 24.2%. The company highlighted robust growth in large pharma, Spatial Biology, and GMP proteins, which partially offset slower spending from emerging biotech.
Bio-Techne (TECH): Do Steady Dividends Amid Soft Sales Reveal Its True Capital Allocation Priorities?
Bio-Techne reported a 2% year-over-year decline in net sales but an increase in net income and EPS for its fiscal third quarter 2026. Despite softer demand, the company affirmed its quarterly cash dividend, indicating a focus on cost discipline and shareholder returns. This suggests Bio-Techne has financial flexibility to invest while rewarding shareholders, although prolonged market weakness remains a risk.
Principal Financial Group Inc. Has $41.37 Million Stock Position in Bio-Techne Corp $TECH
Principal Financial Group Inc. significantly increased its stake in Bio-Techne Corp by 316.7% in the fourth quarter of the prior fiscal year, holding 703,477 shares valued at $41.37 million. This move is part of a larger trend of institutional buying, with hedge funds and asset managers now owning 98.95% of Bio-Techne's stock. Despite analysts holding a "Moderate Buy" rating with an average $66.77 price target, Bio-Techne recently missed its earnings and revenue estimates for the quarter and announced a quarterly dividend of $0.08 per share.
Bio-Techne Corp (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Bio-Techne Corp (NASDAQ:TECH) has received a "Moderate Buy" consensus recommendation from fourteen analysts, with an average one-year price target of $66.77. The company recently reported quarterly EPS of $0.53 and revenue of $311.42 million, both missing estimates, with revenue declining 1.5% year-over-year. Bio-Techne also announced a quarterly dividend of $0.08 per share.
TECH (TECH) Form 144 shows planned option-exercise sales, prior sale by Molho
BIO-TECHNE Corp (TECH) has filed a Form 144 showing planned sales of 2,212 and 4,424 shares related to option exercises scheduled for May 8, 2026, under a registered plan. The filing also indicates a prior sale by Joshua Molho of 1,976 shares on February 17, 2026, which generated $116,791.48. These filings are notices of intent and do not confirm the completion of the planned transactions.
Stephens Adjusts Bio-Techne Price Target to $68 From $80
Stephens has lowered its price target for Bio-Techne (NASDAQ: TECH) shares to $68 from $80. The firm maintained an Equal-Weight rating on the stock. This adjustment reflects a revised valuation perspective by Stephens for the company.
Bio-Techne Corp. stock underperforms Friday when compared to competitors
Bio-Techne Corp. (TECH) stock fell by 5.01% on Friday, closing at $48.36, despite a generally favorable trading session for the broader market. This performance left the company's shares 32.98% below its 52-week high of $72.16 achieved in January. The S&P 500 and Dow Jones Industrial Average both saw gains on the same day.
Why Bio-Techne Is Dropping 5.9%: Citigroup Maintains Buy
Bio-Techne Corporation shares fell 5.9% after three major Wall Street firms collectively cut their price targets by an average of 13.3%, citing concerns about the biotechnology firm’s near-term prospects. Citigroup, Wells Fargo, and Evercore ISI Group all adjusted their targets, signaling increased caution despite two firms maintaining positive ratings. Investors are advised to monitor the company's next quarterly results for potential catalysts or further validation of analyst concerns.
Why Bio-Techne Is Dropping 5.9%: Citigroup Maintains Buy
Bio-Techne Corporation's shares fell 5.9% after three Wall Street firms, including Citigroup, Wells Fargo, and Evercore ISI Group, cut their price targets due to concerns about the biotechnology firm’s near-term prospects. Despite the target reductions, Citigroup and Wells Fargo maintained positive ratings, though the average new target still implies upside from current levels. Investors are advised to watch the upcoming quarterly results for further management commentary on demand trends.
Analyst recommendations: Airbnb , Citigroup , The Walt Disney Company , Block, Cloudflare...
This article provides a daily selection of analyst recommendations for North American companies, focusing on those with changes in opinion, price target, or new coverage. The report includes updates for major companies like Airbnb, Citigroup, The Walt Disney Company, Block, and Cloudflare, detailing rating changes and target price adjustments from various financial institutions. The information aims to offer insights into market sentiment and potential stock movements.
Deutsche Bank Adjusts Bio-Techne Price Target to $66 From $75, Maintains Buy Rating
Deutsche Bank has updated its price target for Bio-Techne (TECH) to $66, down from the previous $75, while reaffirming a Buy rating on the stock. This adjustment comes amidst recent company news, including Bio-Techne missing revenue estimates for its fiscal Q3 and reporting lower adjusted earnings. The article also notes other analysts' price target adjustments for Bio-Techne.
Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Bio-Techne (TECH)
Analysts are presenting conflicting sentiments for healthcare companies BillionToOne, Inc. Class A (BLLN) and Bio-Techne (TECH). William Blair analyst Andrew Brackmann maintained a Buy rating for BillionToOne, while KeyBanc's Paul Knight maintained a Hold rating for Bio-Techne. The article details analyst ratings, price targets, and recent financial updates for both companies, highlighting the divergent views within the sector.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock saw a positive performance of 1.25% to $70.52 on an active trading day, surpassing both its competitors and the broader market. Despite this daily gain, the stock remains significantly below its 52-week high.
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group
April McClain Delaney, a congressional representative from Maryland, has made several stock transactions, including selling shares in Bio-Techne Corp, C.H. Robinson Worldwide, and other companies. Concurrently, she purchased shares in Entegris, Inc., Markel Group Inc., Nasdaq, Inc., Packaging Corporation of America, STERIS plc, and Transdigm Group. These transactions, valued between $1,001 and $50,000 per range, were all conducted in April 2026 and publicly disclosed as part of routine financial management and transparency requirements for members of Congress.
Bio-Techne (TECH) SVP exercises 8,400 options, 7,055 shares withheld for taxes
Bio-Techne's SVP and General Counsel, Shane Bohnen, engaged in routine equity compensation activity, exercising options for 8,400 common shares at $47.60 each. Concurrently, 7,055 shares were withheld at $56.68 per share to cover tax obligations, which is a tax-withholding disposition, not an open-market sale. After these transactions, Bohnen directly owns 14,304 shares of Bio-Techne common stock and retains a substantial number of unexercised options and restricted stock units.
CFO at Bio-Techne (TECH) exercises 62,000 options and settles taxes in shares
Bio-Techne's CFO, James Hippel, recently exercised 62,000 stock options at $47.60 per share. On the same day, 56,955 shares were disposed of at $56.68 per share to cover tax withholding, not as an open-market sale. Following these transactions, Hippel's direct common stock holdings stand at 153,670 shares, with a substantial remaining portfolio of unexercised options and restricted stock units.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock saw a significant increase of 2.15% on a strong trading day, closing at $73.34, outperforming its competitors and the broader market indices. Despite this gain, the stock remains below its 52-week high, and its trading volume was lower than its average.
Citigroup Issues Pessimistic Forecast for Bio-Techne (NASDAQ:TECH) Stock Price
Citigroup has lowered its price target for Bio-Techne (NASDAQ:TECH) from $80.00 to $70.00, though it maintained a "buy" rating, indicating a potential 37.5% upside. This adjustment follows Bio-Techne's Q3 results missing analyst estimates for both EPS and revenue, with the company anticipating flat organic growth for Q4. Despite these concerns and other firms also trimming price targets, Bio-Techne's stock traded up 7.4% on Thursday.
Research Alert: CFRA Lowers Rating On Shares Of Bio-techne Corporation To Sell From Hold
CFRA has downgraded its rating on Bio-techne Corporation (NASDAQ: TECH) shares from Hold to Sell. This adjustment reflects a change in the analyst's outlook for the company's stock performance.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) saw its stock advance by 7.39% to $50.91 on Thursday, outperforming the broader market as the S&P 500 and Dow Jones Industrial Average both fell. Despite the day's gains, the company's stock remains 29.45% below its 52-week high of $72.16 achieved in January. This performance comes amidst a generally rough trading session for the stock market.
Wells Fargo & Company Cuts Bio-Techne (NASDAQ:TECH) Price Target to $62.00
Wells Fargo & Company has lowered its price target for Bio-Techne (NASDAQ:TECH) to $62.00 from $76.00, while maintaining an "overweight" rating. This adjustment follows Bio-Techne's miss on Q3 earnings and revenue estimates, attributing the shortfall to weaker U.S. academic demand and shipment timing. Despite the cut in price target, analyst sentiment remains "Moderate Buy" with a consensus target of $67.54, and major institutions have increased their holdings.
Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion
Bio-Techne anticipates its fourth-quarter organic growth to be approximately flat. The company is also targeting about 100 basis points of margin expansion during the same period.
Bio-Techne Corporation (NASDAQ:TECH) Q3 2026 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH) reported its Q3 2026 earnings, with an adjusted EPS of $0.53, missing expectations of $0.55. Despite a 2% organic revenue decline, driven by softness in emerging biotech spending and order timing for cell therapy customers, the company highlighted strong performance in large pharma, stabilization in U.S. academia, and continued growth in China. Leadership anticipates an acceleration of growth in fiscal year 2027 as market conditions improve and company-specific headwinds subside.
Bio-Techne Earnings: Softness in Biotech Demand Continues to Weigh on Top-Line Growth
Bio-Techne reported a 2% revenue decline and a decrease in adjusted operating income margin for its third fiscal quarter, primarily due to a high single-digit revenue decline from biotech customers. Following this news, the company's shares experienced a significant 16% sell-off. This indicates that continued softness in the biotech sector is impacting Bio-Techne's financial performance.
